Could a common heart drug be safer for patients with two heart conditions?
NCT ID NCT07405671
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares the safety of the drug flecainide against standard treatments (sotalol or amiodarone) in about 988 adults with atrial fibrillation and stable coronary artery disease. Participants will be randomly assigned to one treatment and followed for at least a year to track serious side effects, hospitalizations, and deaths. The goal is to see if flecainide is a safe option for managing heart rhythm in this group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Software-Guided heart procedures: a new standard for coronary care?
- Heart patients may stay active longer with coach calls and group support
- Sitting less could be a lifeline for frail hearts – a new trial tests a simple program
- Can balloon timing make or break heart artery success?
- Can we predict which heart aneurysms will grow?
- Can a higher dose of adenosine sharpen heart scans?